Alvotech (NASDAQ:ALVO) Price Target Lowered to $6.00 at UBS Group

Alvotech (NASDAQ:ALVO) had its price target trimmed by UBS Group from $10.00 to $6.00 in a research report sent to investors on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other equities research analysts have also recently commented on ALVO. Barclays lowered their target price on Alvotech from $5.00 to $4.00 and set an “underweight” rating on the stock in a research note on Tuesday. Zacks Research upgraded shares of Alvotech from a “strong sell” rating to a “hold” rating in a report on Thursday, March 19th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alvotech in a research report on Wednesday, January 21st. Finally, Morgan Stanley set a $10.00 target price on shares of Alvotech in a research note on Wednesday, December 3rd. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Alvotech presently has an average rating of “Hold” and an average target price of $7.60.

Alvotech Trading Down 6.0%

Shares of ALVO opened at $3.13 on Tuesday. The stock has a 50 day moving average of $4.46 and a 200 day moving average of $5.77. The company has a market capitalization of $943.63 million, a price-to-earnings ratio of 31.30 and a beta of 0.16. Alvotech has a 12 month low of $3.03 and a 12 month high of $11.85.

Alvotech (NASDAQ:ALVO) last posted its quarterly earnings data on Wednesday, March 18th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of $0.13 by ($0.50). The business had revenue of $173.20 million during the quarter, compared to analysts’ expectations of $162.20 million. Alvotech had a negative return on equity of 12.84% and a net margin of 4.74%. As a group, equities research analysts predict that Alvotech will post -0.07 earnings per share for the current year.

Hedge Funds Weigh In On Alvotech

A number of large investors have recently made changes to their positions in the stock. Geode Capital Management LLC grew its position in shares of Alvotech by 0.7% in the second quarter. Geode Capital Management LLC now owns 230,291 shares of the company’s stock valued at $2,100,000 after purchasing an additional 1,574 shares in the last quarter. Tempus Wealth Planning LLC lifted its holdings in Alvotech by 6.8% during the 3rd quarter. Tempus Wealth Planning LLC now owns 33,806 shares of the company’s stock worth $277,000 after purchasing an additional 2,154 shares in the last quarter. ProShare Advisors LLC boosted its stake in Alvotech by 24.0% in the 4th quarter. ProShare Advisors LLC now owns 13,826 shares of the company’s stock worth $71,000 after purchasing an additional 2,675 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in Alvotech by 25.7% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,211 shares of the company’s stock worth $78,000 after purchasing an additional 3,110 shares during the period. Finally, JPMorgan Chase & Co. grew its holdings in Alvotech by 30.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 24,455 shares of the company’s stock valued at $200,000 after buying an additional 5,697 shares in the last quarter.

More Alvotech News

Here are the key news stories impacting Alvotech this week:

• Positive Sentiment: UBS reiterated a Buy on ALVO and cut its price target from $10 to $6, framing regulatory setbacks as largely priced in while pointing to underlying biosimilar strength that supports upside. Article Title
• Positive Sentiment: Coverage pieces highlight Alvotech’s ongoing execution in the biosimilar market and argue for continued growth potential, which could be supportive if revenue trends and margin progress continue. Alvotech Charts Course for Continued Growth in Biosimilar Market
• Positive Sentiment: Northland Securities published commentary on Alvotech’s FY2026 results (revenue beat but EPS miss in recent quarter), providing additional analyst attention that may help reprice the stock as investors parse forward guidance and pipeline milestones. Northland Securities Comments on Alvotech FY2026 Earnings
• Neutral Sentiment: Short-interest reports are inconsistent: one clean print shows a meaningful decline to ~2.46M shares short (≈0.8% of shares) as of March 13 with a short-interest ratio ~3.7 days — a modest short base. However, multiple March 23–24 data entries report “0 shares” (likely reporting glitches), so short-interest trends should be treated cautiously.
• Negative Sentiment: Barclays cut its price target from $5 to $4 and maintained an Underweight rating, a bearish signal that likely pressured the stock alongside broader downgrades. Article Title
• Negative Sentiment: Analyst target reductions overall (UBS lowered its PT despite keeping a Buy; Barclays trimmed target and kept Underweight) increase near-term uncertainty and likely contributed to the share decline as investors weigh regulatory risk, earnings misses, and execution against long-term biosimilar opportunity. Alvotech: Regulatory Setbacks Priced In…

Alvotech Company Profile

Alvotech (NASDAQ:ALVO) is a global biopharmaceutical company specializing in the development, manufacturing and commercialization of biosimilar medicines. The company focuses on creating high‐quality, cost‐effective alternatives to established biologic therapies in areas such as immunology, oncology and other specialty care fields. By leveraging in‐house research and a vertically integrated manufacturing platform, Alvotech aims to bring approved biosimilars to market more rapidly and with greater cost efficiency than many traditional biosimilar developers.

Since its founding in 2013, Alvotech has built a diversified pipeline of monoclonal antibody biosimilars, targeting blockbuster reference products including adalimumab (originally branded Humira), bevacizumab (Avastin) and ustekinumab (Stelara).